• Users Online: 120
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 8  |  Issue : 1  |  Page : 7-11

Spectrum of BCR-ABL1 kinase domain mutations: A cohort study from Saudi Arabia


Department of Pathology and Laboratory Medicine, MBC 10 King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia

Correspondence Address:
Halah Abalkhail
Department of Pathology and Laboratory Medicine, MBC 10King Faisal Specialist Hospital and Research Centre, Riyadh 11211
Kingdom of Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joah.joah_52_16

Rights and Permissions

Background: The BCR-ABL1 tyrosine kinase domain mutation constitutes a major cause of resistance to the tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). In this retrospective study, we assessed the ABL kinase domain mutation in 123 patients (61 females and 62 males) aged 10–79 years (median age of 50 years). These patients were referred to our clinics at King Faisal Specialist Hospital and Research Center (General Organization), Riyadh, Kingdom of Saudi Arabia during period (2011–2014). These patients had Philadelphia-positive CML displaying either failure to tyrosine kinase inhibitor (TKI) or suboptimal response with increased BCR-ABL1 levels through serial monitoring by using quantitative Real time PCR. Methods: The mutation analysis was performed on RNA extracted from Peripheral blood samples after the amplification of the BCR-ABL1 transcript by nested PCR followed by direct sequencing of the BCR-ABL1 kinase domain including the residues (243–487). Results: Of 123 patients, 119 adults and four pediatrics were analyzed. From the total, 25 (20%) were tested positive for 11 different mutations in the ABL1 kinase domain (11 patients with T315I, 3 with Y253H, 2 with E255K, 2 F317L, and 1 patient having each of the following mutations: F359I, E355G, V299L, L248V, L298, M244V, and Y326H). The duration from the diagnosis to mutation detection ranged between 3 and 144 months with a median duration of four years. Conclusion: Despite the retrospective nature of the study and relatively small sample size of a single center analysis, the mutation frequency is in line with similar reported studies from other parts of the world.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed504    
    Printed16    
    Emailed0    
    PDF Downloaded88    
    Comments [Add]    

Recommend this journal